CRIS Current Research Information System

DI FEDERICO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.316
NA - Nord America 2.236
EU - Europa 1.676
AF - Africa 201
SA - Sud America 201
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.635
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.185
VN - Vietnam 1.175
CN - Cina 1.100
SG - Singapore 1.062
IT - Italia 656
HK - Hong Kong 332
NL - Olanda 175
DE - Germania 169
IN - India 168
KR - Corea 163
BR - Brasile 139
SE - Svezia 120
FR - Francia 97
GB - Regno Unito 97
FI - Finlandia 91
JP - Giappone 65
IE - Irlanda 63
CI - Costa d'Avorio 62
CH - Svizzera 55
RU - Federazione Russa 38
PH - Filippine 37
AR - Argentina 35
TG - Togo 35
TH - Thailandia 35
SC - Seychelles 31
CA - Canada 30
ID - Indonesia 30
JO - Giordania 27
NG - Nigeria 26
AT - Austria 24
ZA - Sudafrica 21
IQ - Iraq 19
MX - Messico 19
PL - Polonia 19
TR - Turchia 16
ES - Italia 14
PK - Pakistan 14
TW - Taiwan 13
BD - Bangladesh 12
BG - Bulgaria 12
BE - Belgio 9
LT - Lituania 8
UA - Ucraina 8
CL - Cile 6
EC - Ecuador 6
UZ - Uzbekistan 6
DZ - Algeria 5
KE - Kenya 5
MY - Malesia 5
OM - Oman 5
SA - Arabia Saudita 5
VE - Venezuela 5
AE - Emirati Arabi Uniti 4
GR - Grecia 4
MA - Marocco 4
PY - Paraguay 4
AL - Albania 3
AZ - Azerbaigian 3
CO - Colombia 3
EG - Egitto 3
IL - Israele 3
KZ - Kazakistan 3
NP - Nepal 3
PT - Portogallo 3
BY - Bielorussia 2
HR - Croazia 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
NZ - Nuova Zelanda 2
PE - Perù 2
SN - Senegal 2
TN - Tunisia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AO - Angola 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
DK - Danimarca 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
GM - Gambi 1
IS - Islanda 1
JM - Giamaica 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LY - Libia 1
ML - Mali 1
MM - Myanmar 1
MT - Malta 1
NI - Nicaragua 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
UY - Uruguay 1
Totale 8.635
Salva come PNG Salva come JPEG
Città #
Singapore 756
Ashburn 364
Hefei 339
Hong Kong 310
Ho Chi Minh City 294
Hanoi 266
San Jose 221
Dallas 168
Seoul 144
Santa Clara 138
Beijing 132
Bologna 129
Chandler 116
Boardman 73
Abidjan 62
Dublin 62
Fairfield 61
Helsinki 61
Council Bluffs 58
Los Angeles 58
Milan 57
Dong Ket 54
New York 49
Tokyo 44
Bern 43
Lauterbourg 41
Seattle 39
Haiphong 38
Princeton 37
Southend 36
Lomé 35
Rome 34
Houston 33
Hyderabad 33
Munich 33
Bengaluru 31
Buffalo 30
Frankfurt am Main 30
Turin 29
Da Nang 28
Shanghai 27
Amman 25
Redondo Beach 24
Woodbridge 24
Cinquefrondi 22
Guangzhou 21
Hải Dương 21
Abeokuta 20
Biên Hòa 20
Falkenstein 19
Wilmington 19
Jakarta 17
Amsterdam 16
São Paulo 16
Tianjin 16
Turku 16
Visakhapatnam 16
Can Tho 15
Messina 15
Modena 15
Johannesburg 14
London 14
Orem 14
Stockholm 14
Cambridge 13
Lappeenranta 13
The Dalles 13
Tongling 13
Quận Bình Thạnh 12
San Diego 12
Warsaw 12
Montreal 11
Sofia 11
Xi'an 11
Atlanta 10
Ha Long 10
Moncalieri 10
Ninh Bình 10
Poplar 10
Toronto 10
Vienna 10
Bắc Giang 9
Florence 9
Nuremberg 9
Quận Một 9
Zhengzhou 9
Bangkok 8
Boydton 8
Brooklyn 8
Bắc Ninh 8
Chicago 8
Thái Nguyên 8
Berlin 7
Boston 7
Brussels 7
Chennai 7
Elk Grove Village 7
Hangzhou 7
Jinan 7
Manila 7
Totale 5.346
Salva come PNG Salva come JPEG
Nome #
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience 270
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy 257
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 230
STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status 218
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 198
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes 195
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations 189
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma 184
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors 182
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC) 177
The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma—letter 175
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 175
Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience 165
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 164
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution 160
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 159
Peripheral nervous system adverse events associated with immune checkpoint inhibitors 157
The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma 157
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? 157
Hacking pancreatic cancer: Present and future of personalized medicine 157
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 156
Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond 148
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors 147
Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report 145
Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible? 145
Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) 139
The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma 130
Advanced non-small-cell lung cancer: how to manage non-oncogene disease 129
Critical diagnostic delay associated with unusual presentation of hepatocellular carcinoma (Hcc) with orbital metastases: A case report 129
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC 126
Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients 126
STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive? 125
Early monitoring of plasma KRAS G12C with digital PCR predicts antitumor response to immunotherapy or sotorasib in advanced NSCLC: A brief report 120
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer 119
18F-Fluorodeoxyglucose Uptake in PDGFRA-Mutant Gastrointestinal Stromal Tumors 117
Histopathological Evidence for a Non-Inflammatory Mechanism in Osimertinib-Induced Myopathy: A Case Report 115
Acute kidney injury as a possible immune-related adverse event associated with sustained complete response to BRAF and MEK inhibitors in advanced, V600E-mutated melanoma 113
Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis 111
PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis 111
Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib 109
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer 106
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study 103
Nivolumab: an investigational agent for the treatment of biliary tract cancer 101
Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis 99
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer 99
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials 98
Paraneoplastic vs. non-paraneoplastic anti-Hu associated dysmotility: a case series and literature review 96
First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis 87
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review 86
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue 86
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer 84
PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy 84
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies 83
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma 80
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 80
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines) 74
Should We Test Cancer Susceptibility Genes in Routinely Used Multigene Panels? A Case of Synchronous Lung Adenocarcinoma and Breast Cancer Associated With Germline CHEK2 Mutation 73
EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature 71
Prognostic relevance of pleural invasion for resected NSCLC patients undergoing adjuvant treatments: A propensity score-matched analysis of SEER database 69
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC 67
IMpower 132: Is the Second Exception to the Rule No Longer an Exception? 66
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC 60
Navigating challenges in EGFR exon 20 insertions: The PAPILLON trial unravels the promise of amivantamab-chemotherapy 59
Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: Rationale and clinical implication 58
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? 58
Title: Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer 52
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects 49
Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities 48
Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50% 36
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC 36
Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer 34
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study 32
Efficacy and Safety of TROP-2-Targeting Antibody–Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data 29
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis 29
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity 27
Advances in Novel Systemic Therapies for Advanced Hepatocellular Carcinoma 27
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry 26
Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study 25
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry 25
Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis 22
Letter Re: Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations 20
Totale 8.830
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.259
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.259
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202185 0 0 0 0 0 0 0 0 0 8 7 70
2021/2022355 15 1 4 17 16 8 4 49 50 25 119 47
2022/2023734 38 77 35 42 102 57 29 51 141 40 50 72
2023/2024359 45 33 19 25 21 65 13 41 13 33 38 13
2024/20252.078 89 145 176 119 216 102 216 93 46 216 211 449
2025/20265.056 673 620 499 441 372 252 534 189 1.058 418 0 0
Totale 8.830